Developmental and Epileptic Encephalopathy
📧 Sign up to get email alerts when something new happens for Developmental and Epileptic Encephalopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy [Phase 2]
This report covers a long-term, open-label Phase 2 safety study of LP352 in developmental and epileptic encephalopathy, including Dravet and…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Melatonin for the Treatment of DEE-SWAS [Phase 2]
Phase 2 clinical trial evaluating melatonin for treatment of electrical status epilepticus in sleep and related developmental epileptic ence…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy [Phase 1, Phase 2]
A clinical trial update indicates that the CAP-002 gene therapy trial in pediatric STXBP1-related encephalopathy (a developmental and epilep…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies [Phase 1, Phase 2]
Clinical trial update indicates LP352 has completed Phase 1/2 studies in developmental and epileptic encephalopathies. The program covers Dr…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy [Phase 3]
Phase 3 trial of XEN496 (ezogabine) in children with KCNQ2 developmental and epileptic encephalopathy was terminated with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-01-10Clinical Trial Update: Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies [Phase 1, Phase 2]
A Phase 1/2 clinical trial of TAK-935 as an adjunctive therapy for developmental and/or epileptic encephalopathies has been completed with r…